Partial Response to erdafitinib in FGFR3::TACC3 Fusion–Positive Sinonasal Mucosal Melanoma: A Case Report
Case Reports in Oncology · 2026-11-05
DOI: 10.1159/cro/abzag091 ↗Abstract
Abstract Introduction: Sinonasal mucosal melanoma (SNMM) is a rare and biologically aggressive melanoma subtype associated with high rates of locoregional recurrence, early distant metastasis, and poor long-term survival. While surgery and radiotherapy remain the cornerstone of treatment for localized disease, systemic options for advanced or refractory SNMM are limited, and responses to immune checkpoint inhibitors are inferior to those observed in cutaneous melanoma. Comprehensive molecular profiling has therefore become increasingly important to identify actionable genomic alterations and guide precision oncology approaches. Case presentation: We report a case of FGFR3::TACC3 fusion–positive sinonasal mucosal melanoma achieving clinical and radiologic benefit from off-label treatment with the FGFR inhibitor erdafitinib. After multiple locoregional recurrences and systemic progression following surgery, adjuvant radiotherapy, and combined nivolumab–ipilimumab, comprehensive molecular profiling identified an actionable FGFR3::TACC3 fusion. Treatment with erdafitinib resulted in rapid symptomatic improvement and initial partial response according to RECIST v1.1, with toxicities that were predictable, manageable, and consistent with the known FGFR-inhibitor safety profile. Progression-free survival was seven months. Conclusion: This case highlights the clinical relevance of molecularly guided, tumor-agnostic therapeutic strategies in rare melanoma subtypes with limited standard-of-care options and supports the integration of comprehensive genomic profiling into the management of refractory SNMM.
EUVIMED